The key clinical trial: Kim et al., 2018
Journal of Medicinal Food, 2018. Double-blind, placebo-controlled RCT. PMID: 29688793
Study design
A 12-week randomised, double-blind, placebo-controlled trial conducted in Korea. 90 obese adults (BMI 25–35) were randomly assigned to one of three groups: placebo, low-dose L. gasseri BNR17 (1 billion CFU/day), or high-dose L. gasseri BNR17 (10 billion CFU/day — the same dose in every BNRThin Slim+ stick). Participants maintained their usual diet and activity levels throughout the study. Outcomes were measured at baseline, 6 weeks, and 12 weeks.
Primary outcome: visceral adipose tissue (VAT)
The primary endpoint was change in visceral adipose tissue (VAT) — the metabolically active fat surrounding internal organs, measured by CT scan. At 12 weeks, the high-dose BNR17 group showed a statistically significant reduction in VAT compared to the placebo group: −21.6 cm² difference (P = 0.012). The low-dose group showed a trend toward reduction but did not reach statistical significance for VAT versus placebo.
Secondary outcomes: waist circumference
Waist circumference was significantly reduced in both BNR17 groups compared to their own baseline measurements: low-dose (P = 0.045) and high-dose (P = 0.012). This is a secondary outcome measured versus baseline, not versus placebo. The placebo group did not show a significant change in waist circumference.
What the study did NOT show
Total body weight was not significantly different between groups. Blood lipids (total cholesterol, LDL, HDL, triglycerides), fasting glucose, and fasting insulin did not differ significantly between groups at any timepoint. The study authors did not claim weight loss, cholesterol-lowering, or blood sugar effects, and neither do we. We will not represent this study as showing more than it does.
Safety
No adverse reactions were reported in any group throughout the 12-week trial. BNR17 at both 1 billion and 10 billion CFU/day was well tolerated.
Full citation
Kim J, Yun JM, Kim MK, Kwon O, Cho B. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults. J Med Food. 2018;21(5):454–461. doi: 10.1089/jmf.2017.3937 — PubMed PMID: 29688793
Clinical study conducted in Korea. Results may not generalize to all populations. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Best results with a balanced diet and regular exercise.
Earlier research: Jung et al., 2013
Beneficial Microbes, 2013. PMC3611107
Prior to the 2018 RCT, Jung et al. (2013) conducted an earlier human study on L. gasseri BNR17 that established initial safety and tolerability data in human subjects. The study provided early evidence supporting further clinical investigation of the strain, forming the scientific foundation on which the 2018 double-blind RCT was built. BNR17 was well tolerated across all participants, with no adverse events attributed to the probiotic intervention.
This product is not intended to diagnose, treat, cure, or prevent any disease.
Proposed mechanism of action
The precise mechanism by which L. gasseri BNR17 may support body composition is not yet fully characterised. Based on current research and the broader literature on the gut–adipose axis, several pathways have been proposed.
Gut microbiome modulation: BNR17 may modulate the composition and activity of the gut microbiome. Shifts in microbial populations are associated with changes in short-chain fatty acid (SCFA) production, which may influence energy extraction from food and fat storage signalling.
Lipid metabolism pathways: Emerging research suggests that certain Lactobacillus gasseri strains may modulate enzymes involved in lipid metabolism, including lipase activity and bile acid cycling, potentially influencing how dietary fats are processed and stored.
Adipogenesis: Some research suggests that specific probiotic strains may modulate gene expression pathways related to adipogenesis — the formation of fat cells — though the clinical significance of this pathway for BNR17 specifically remains under investigation.
Mechanistic pathways described above are proposed based on current research. They do not constitute established medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
MFDS recognition: what it means
Korea’s Ministry of Food & Drug Safety (MFDS) is the Korean government’s primary food and drug regulatory authority — broadly equivalent in function to the US FDA or European EFSA. MFDS reviews the scientific evidence for specific functional ingredients and, where the evidence meets their standard, grants formal recognition of that ingredient for a defined health function.
Lactobacillus gasseri BNR17 has received MFDS recognition as a functional ingredient in the body composition category — making it among the first individual probiotic strains to receive this specific recognition in Korea. This recognition applies to the strain at the studied dose (10 billion CFU/day).
Important clarification: MFDS recognition is a Korean regulatory status. It does not constitute an approved health claim under Malaysian law (NPRA/KKM). We present MFDS recognition as evidence of the scientific rigour applied to BNR17 in its country of origin, not as a Malaysian medical claim.
Safety & quality standards
GMP manufacturing
Produced in a GMP-certified facility in South Korea. GMP (Good Manufacturing Practice) is the same quality standard applied to pharmaceutical manufacturing. Every batch is tested for potency, purity, and strain identity before release.
CFU guarantee at expiry
The 10 billion CFU stated on the label is guaranteed at the best-before date — not just at manufacture. This is a higher standard than most probiotic products, made possible by AceBiome’s proprietary 3-phase desiccant system inside each sachet.
Allergens & suitability
No allergens declared. May contain traces of dairy (shared facility). Gluten-free. Soy-free. No gelatin. No pork derivatives. Suitable for vegetarians. Store below 25°C — no refrigeration needed during use or transit.
Bibliography
- Kim J, Yun JM, Kim MK, Kwon O, Cho B. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults. J Med Food. 2018;21(5):454–461. doi: 10.1089/jmf.2017.3937. PMID: 29688793. PubMed
- Jung SP, Lee KM, Kang JH, et al. Effect of Lactobacillus gasseri BNR17 on Overweight and Obese Adults: A Randomized, Double-Blind Clinical Trial. Korean J Fam Med. 2013;34(2):80–89. doi: 10.4082/kjfm.2013.34.2.80. PMC3611107. PMC
This page is for informational purposes only. Clinical study results are presented accurately and without exaggeration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
The key clinical trial: Kim et al., 2018
Journal of Medicinal Food, 2018. Double-blind, placebo-controlled RCT. PMID: 29688793
Study design
A 12-week randomised, double-blind, placebo-controlled trial conducted in Korea. 90 obese adults (BMI 25–35) were randomly assigned to one of three groups: placebo, low-dose L. gasseri BNR17 (1 billion CFU/day), or high-dose L. gasseri BNR17 (10 billion CFU/day — the same dose in every BNRThin Slim+ stick). Participants maintained their usual diet and activity levels throughout the study. Outcomes were measured at baseline, 6 weeks, and 12 weeks.
Primary outcome: visceral adipose tissue (VAT)
The primary endpoint was change in visceral adipose tissue (VAT) — the metabolically active fat surrounding internal organs, measured by CT scan. At 12 weeks, the high-dose BNR17 group showed a statistically significant reduction in VAT compared to the placebo group: −21.6 cm² difference (P = 0.012). The low-dose group showed a trend toward reduction but did not reach statistical significance for VAT versus placebo.
Secondary outcomes: waist circumference
Waist circumference was significantly reduced in both BNR17 groups compared to their own baseline measurements: low-dose (P = 0.045) and high-dose (P = 0.012). This is a secondary outcome measured versus baseline, not versus placebo. The placebo group did not show a significant change in waist circumference.
What the study did NOT show
Total body weight was not significantly different between groups. Blood lipids (total cholesterol, LDL, HDL, triglycerides), fasting glucose, and fasting insulin did not differ significantly between groups at any timepoint. The study authors did not claim weight loss, cholesterol-lowering, or blood sugar effects, and neither do we. We will not represent this study as showing more than it does.
Safety
No adverse reactions were reported in any group throughout the 12-week trial. BNR17 at both 1 billion and 10 billion CFU/day was well tolerated.
Full citation
Kim J, Yun JM, Kim MK, Kwon O, Cho B. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults. J Med Food. 2018;21(5):454–461. doi: 10.1089/jmf.2017.3937 — PubMed PMID: 29688793
Clinical study conducted in Korea. Results may not generalize to all populations. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Best results with a balanced diet and regular exercise.
Earlier research: Jung et al., 2013
Beneficial Microbes, 2013. PMC3611107
Prior to the 2018 RCT, Jung et al. (2013) conducted an earlier human study on L. gasseri BNR17 that established initial safety and tolerability data in human subjects. The study provided early evidence supporting further clinical investigation of the strain, forming the scientific foundation on which the 2018 double-blind RCT was built. BNR17 was well tolerated across all participants, with no adverse events attributed to the probiotic intervention.
This product is not intended to diagnose, treat, cure, or prevent any disease.
Proposed mechanism of action
The precise mechanism by which L. gasseri BNR17 may support body composition is not yet fully characterised. Based on current research and the broader literature on the gut–adipose axis, several pathways have been proposed.
Gut microbiome modulation: BNR17 may modulate the composition and activity of the gut microbiome. Shifts in microbial populations are associated with changes in short-chain fatty acid (SCFA) production, which may influence energy extraction from food and fat storage signalling.
Lipid metabolism pathways: Emerging research suggests that certain Lactobacillus gasseri strains may modulate enzymes involved in lipid metabolism, including lipase activity and bile acid cycling, potentially influencing how dietary fats are processed and stored.
Adipogenesis: Some research suggests that specific probiotic strains may modulate gene expression pathways related to adipogenesis — the formation of fat cells — though the clinical significance of this pathway for BNR17 specifically remains under investigation.
Mechanistic pathways described above are proposed based on current research. They do not constitute established medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
MFDS recognition: what it means
Korea’s Ministry of Food & Drug Safety (MFDS) is the Korean government’s primary food and drug regulatory authority — broadly equivalent in function to the US FDA or European EFSA. MFDS reviews the scientific evidence for specific functional ingredients and, where the evidence meets their standard, grants formal recognition of that ingredient for a defined health function.
Lactobacillus gasseri BNR17 has received MFDS recognition as a functional ingredient in the body composition category — making it among the first individual probiotic strains to receive this specific recognition in Korea. This recognition applies to the strain at the studied dose (10 billion CFU/day).
Important clarification: MFDS recognition is a Korean regulatory status. It does not constitute an approved health claim under Malaysian law (NPRA/KKM). We present MFDS recognition as evidence of the scientific rigour applied to BNR17 in its country of origin, not as a Malaysian medical claim.
Safety & quality standards
GMP manufacturing
Produced in a GMP-certified facility in South Korea. GMP (Good Manufacturing Practice) is the same quality standard applied to pharmaceutical manufacturing. Every batch is tested for potency, purity, and strain identity before release.
CFU guarantee at expiry
The 10 billion CFU stated on the label is guaranteed at the best-before date — not just at manufacture. This is a higher standard than most probiotic products, made possible by AceBiome’s proprietary 3-phase desiccant system inside each sachet.
Allergens & suitability
No allergens declared. May contain traces of dairy (shared facility). Gluten-free. Soy-free. No gelatin. No pork derivatives. Suitable for vegetarians. Store below 25°C — no refrigeration needed during use or transit.
Bibliography
- Kim J, Yun JM, Kim MK, Kwon O, Cho B. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults. J Med Food. 2018;21(5):454–461. doi: 10.1089/jmf.2017.3937. PMID: 29688793. PubMed
- Jung SP, Lee KM, Kang JH, et al. Effect of Lactobacillus gasseri BNR17 on Overweight and Obese Adults: A Randomized, Double-Blind Clinical Trial. Korean J Fam Med. 2013;34(2):80–89. doi: 10.4082/kjfm.2013.34.2.80. PMC3611107. PMC
This page is for informational purposes only. Clinical study results are presented accurately and without exaggeration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
The key clinical trial: Kim et al., 2018
Journal of Medicinal Food, 2018. Double-blind, placebo-controlled RCT. PMID: 29688793
Study design
A 12-week randomised, double-blind, placebo-controlled trial conducted in Korea. 90 obese adults (BMI 25–35) were randomly assigned to one of three groups: placebo, low-dose L. gasseri BNR17 (1 billion CFU/day), or high-dose L. gasseri BNR17 (10 billion CFU/day — the same dose in every BNRThin Slim+ stick). Participants maintained their usual diet and activity levels throughout the study. Outcomes were measured at baseline, 6 weeks, and 12 weeks.
Primary outcome: visceral adipose tissue (VAT)
The primary endpoint was change in visceral adipose tissue (VAT) — the metabolically active fat surrounding internal organs, measured by CT scan. At 12 weeks, the high-dose BNR17 group showed a statistically significant reduction in VAT compared to the placebo group: −21.6 cm² difference (P = 0.012). The low-dose group showed a trend toward reduction but did not reach statistical significance for VAT versus placebo.
Secondary outcomes: waist circumference
Waist circumference was significantly reduced in both BNR17 groups compared to their own baseline measurements: low-dose (P = 0.045) and high-dose (P = 0.012). This is a secondary outcome measured versus baseline, not versus placebo. The placebo group did not show a significant change in waist circumference.
What the study did NOT show
Total body weight was not significantly different between groups. Blood lipids (total cholesterol, LDL, HDL, triglycerides), fasting glucose, and fasting insulin did not differ significantly between groups at any timepoint. The study authors did not claim weight loss, cholesterol-lowering, or blood sugar effects, and neither do we. We will not represent this study as showing more than it does.
Safety
No adverse reactions were reported in any group throughout the 12-week trial. BNR17 at both 1 billion and 10 billion CFU/day was well tolerated.
Full citation
Kim J, Yun JM, Kim MK, Kwon O, Cho B. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults. J Med Food. 2018;21(5):454–461. doi: 10.1089/jmf.2017.3937 — PubMed PMID: 29688793
Clinical study conducted in Korea. Results may not generalize to all populations. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Best results with a balanced diet and regular exercise.
Earlier research: Jung et al., 2013
Beneficial Microbes, 2013. PMC3611107
Prior to the 2018 RCT, Jung et al. (2013) conducted an earlier human study on L. gasseri BNR17 that established initial safety and tolerability data in human subjects. The study provided early evidence supporting further clinical investigation of the strain, forming the scientific foundation on which the 2018 double-blind RCT was built. BNR17 was well tolerated across all participants, with no adverse events attributed to the probiotic intervention.
This product is not intended to diagnose, treat, cure, or prevent any disease.
Proposed mechanism of action
The precise mechanism by which L. gasseri BNR17 may support body composition is not yet fully characterised. Based on current research and the broader literature on the gut–adipose axis, several pathways have been proposed.
Gut microbiome modulation: BNR17 may modulate the composition and activity of the gut microbiome. Shifts in microbial populations are associated with changes in short-chain fatty acid (SCFA) production, which may influence energy extraction from food and fat storage signalling.
Lipid metabolism pathways: Emerging research suggests that certain Lactobacillus gasseri strains may modulate enzymes involved in lipid metabolism, including lipase activity and bile acid cycling, potentially influencing how dietary fats are processed and stored.
Adipogenesis: Some research suggests that specific probiotic strains may modulate gene expression pathways related to adipogenesis — the formation of fat cells — though the clinical significance of this pathway for BNR17 specifically remains under investigation.
Mechanistic pathways described above are proposed based on current research. They do not constitute established medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
MFDS recognition: what it means
Korea’s Ministry of Food & Drug Safety (MFDS) is the Korean government’s primary food and drug regulatory authority — broadly equivalent in function to the US FDA or European EFSA. MFDS reviews the scientific evidence for specific functional ingredients and, where the evidence meets their standard, grants formal recognition of that ingredient for a defined health function.
Lactobacillus gasseri BNR17 has received MFDS recognition as a functional ingredient in the body composition category — making it among the first individual probiotic strains to receive this specific recognition in Korea. This recognition applies to the strain at the studied dose (10 billion CFU/day).
Important clarification: MFDS recognition is a Korean regulatory status. It does not constitute an approved health claim under Malaysian law (NPRA/KKM). We present MFDS recognition as evidence of the scientific rigour applied to BNR17 in its country of origin, not as a Malaysian medical claim.
Safety & quality standards
GMP manufacturing
Produced in a GMP-certified facility in South Korea. GMP (Good Manufacturing Practice) is the same quality standard applied to pharmaceutical manufacturing. Every batch is tested for potency, purity, and strain identity before release.
CFU guarantee at expiry
The 10 billion CFU stated on the label is guaranteed at the best-before date — not just at manufacture. This is a higher standard than most probiotic products, made possible by AceBiome’s proprietary 3-phase desiccant system inside each sachet.
Allergens & suitability
No allergens declared. May contain traces of dairy (shared facility). Gluten-free. Soy-free. No gelatin. No pork derivatives. Suitable for vegetarians. Store below 25°C — no refrigeration needed during use or transit.
Bibliography
- Kim J, Yun JM, Kim MK, Kwon O, Cho B. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults. J Med Food. 2018;21(5):454–461. doi: 10.1089/jmf.2017.3937. PMID: 29688793. PubMed
- Jung SP, Lee KM, Kang JH, et al. Effect of Lactobacillus gasseri BNR17 on Overweight and Obese Adults: A Randomized, Double-Blind Clinical Trial. Korean J Fam Med. 2013;34(2):80–89. doi: 10.4082/kjfm.2013.34.2.80. PMC3611107. PMC
This page is for informational purposes only. Clinical study results are presented accurately and without exaggeration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
The key clinical trial: Kim et al., 2018
Journal of Medicinal Food, 2018. Double-blind, placebo-controlled RCT. PMID: 29688793
Study design
A 12-week randomised, double-blind, placebo-controlled trial conducted in Korea. 90 obese adults (BMI 25–35) were randomly assigned to one of three groups: placebo, low-dose L. gasseri BNR17 (1 billion CFU/day), or high-dose L. gasseri BNR17 (10 billion CFU/day — the same dose in every BNRThin Slim+ stick). Participants maintained their usual diet and activity levels throughout the study. Outcomes were measured at baseline, 6 weeks, and 12 weeks.
Primary outcome: visceral adipose tissue (VAT)
The primary endpoint was change in visceral adipose tissue (VAT) — the metabolically active fat surrounding internal organs, measured by CT scan. At 12 weeks, the high-dose BNR17 group showed a statistically significant reduction in VAT compared to the placebo group: −21.6 cm² difference (P = 0.012). The low-dose group showed a trend toward reduction but did not reach statistical significance for VAT versus placebo.
Secondary outcomes: waist circumference
Waist circumference was significantly reduced in both BNR17 groups compared to their own baseline measurements: low-dose (P = 0.045) and high-dose (P = 0.012). This is a secondary outcome measured versus baseline, not versus placebo. The placebo group did not show a significant change in waist circumference.
What the study did NOT show
Total body weight was not significantly different between groups. Blood lipids (total cholesterol, LDL, HDL, triglycerides), fasting glucose, and fasting insulin did not differ significantly between groups at any timepoint. The study authors did not claim weight loss, cholesterol-lowering, or blood sugar effects, and neither do we. We will not represent this study as showing more than it does.
Safety
No adverse reactions were reported in any group throughout the 12-week trial. BNR17 at both 1 billion and 10 billion CFU/day was well tolerated.
Full citation
Kim J, Yun JM, Kim MK, Kwon O, Cho B. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults. J Med Food. 2018;21(5):454–461. doi: 10.1089/jmf.2017.3937 — PubMed PMID: 29688793
Clinical study conducted in Korea. Results may not generalize to all populations. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Best results with a balanced diet and regular exercise.
Earlier research: Jung et al., 2013
Beneficial Microbes, 2013. PMC3611107
Prior to the 2018 RCT, Jung et al. (2013) conducted an earlier human study on L. gasseri BNR17 that established initial safety and tolerability data in human subjects. The study provided early evidence supporting further clinical investigation of the strain, forming the scientific foundation on which the 2018 double-blind RCT was built. BNR17 was well tolerated across all participants, with no adverse events attributed to the probiotic intervention.
This product is not intended to diagnose, treat, cure, or prevent any disease.
Proposed mechanism of action
The precise mechanism by which L. gasseri BNR17 may support body composition is not yet fully characterised. Based on current research and the broader literature on the gut–adipose axis, several pathways have been proposed.
Gut microbiome modulation: BNR17 may modulate the composition and activity of the gut microbiome. Shifts in microbial populations are associated with changes in short-chain fatty acid (SCFA) production, which may influence energy extraction from food and fat storage signalling.
Lipid metabolism pathways: Emerging research suggests that certain Lactobacillus gasseri strains may modulate enzymes involved in lipid metabolism, including lipase activity and bile acid cycling, potentially influencing how dietary fats are processed and stored.
Adipogenesis: Some research suggests that specific probiotic strains may modulate gene expression pathways related to adipogenesis — the formation of fat cells — though the clinical significance of this pathway for BNR17 specifically remains under investigation.
Mechanistic pathways described above are proposed based on current research. They do not constitute established medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
MFDS recognition: what it means
Korea’s Ministry of Food & Drug Safety (MFDS) is the Korean government’s primary food and drug regulatory authority — broadly equivalent in function to the US FDA or European EFSA. MFDS reviews the scientific evidence for specific functional ingredients and, where the evidence meets their standard, grants formal recognition of that ingredient for a defined health function.
Lactobacillus gasseri BNR17 has received MFDS recognition as a functional ingredient in the body composition category — making it among the first individual probiotic strains to receive this specific recognition in Korea. This recognition applies to the strain at the studied dose (10 billion CFU/day).
Important clarification: MFDS recognition is a Korean regulatory status. It does not constitute an approved health claim under Malaysian law (NPRA/KKM). We present MFDS recognition as evidence of the scientific rigour applied to BNR17 in its country of origin, not as a Malaysian medical claim.
Safety & quality standards
GMP manufacturing
Produced in a GMP-certified facility in South Korea. GMP (Good Manufacturing Practice) is the same quality standard applied to pharmaceutical manufacturing. Every batch is tested for potency, purity, and strain identity before release.
CFU guarantee at expiry
The 10 billion CFU stated on the label is guaranteed at the best-before date — not just at manufacture. This is a higher standard than most probiotic products, made possible by AceBiome’s proprietary 3-phase desiccant system inside each sachet.
Allergens & suitability
No allergens declared. May contain traces of dairy (shared facility). Gluten-free. Soy-free. No gelatin. No pork derivatives. Suitable for vegetarians. Store below 25°C — no refrigeration needed during use or transit.
Bibliography
- Kim J, Yun JM, Kim MK, Kwon O, Cho B. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults. J Med Food. 2018;21(5):454–461. doi: 10.1089/jmf.2017.3937. PMID: 29688793. PubMed
- Jung SP, Lee KM, Kang JH, et al. Effect of Lactobacillus gasseri BNR17 on Overweight and Obese Adults: A Randomized, Double-Blind Clinical Trial. Korean J Fam Med. 2013;34(2):80–89. doi: 10.4082/kjfm.2013.34.2.80. PMC3611107. PMC
This page is for informational purposes only. Clinical study results are presented accurately and without exaggeration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.